Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02870244 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fieldsv3
  2. Interventions: Dose 1 (Biological), Dose 2 (Biological), Dose 3 (Biological) to Escalating Doses (Biological)
    • Secondary endpoints: details revised at 4 of 4 entries
    • Study arms: 3 to 1
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Loyola University
22 trials monitored
See 1 trial at risk
Melanoma
1,092 trials monitored
See 60 trials at risk
Phase I clinical trial to determine the Phase II dose of autologous TIL 1383I TCR gene modified T Cells using a retrovirus. This is a novel National Cancer Institute (NCI) funded investigator initiated therapy for patients with advanced melanoma.
Trial Details
NCT Number NCT02870244
Lead Sponsor Loyola University
Collaborators: National Cancer Institute (NCI)
Conditions
(from sponsor)		 Melanoma
Related terms Melanoma
Enrollment 18 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov